A carregar...
ACTR-95. HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY
INTRODUCTION: TH-302 (evophosphamide) is a hypoxia-activated prodrug that, when activated in hypoxic conditions (<0.5% O2), releases the bis-alkylating agent bromo-isophosphoramide mustard (Br-IPM), which can then act as a DNA crosslinking agent. In vivo, TH-302 has shown to potentiate the anti-t...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692401/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.079 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|